Alltera

Lopinavir belongs to the class of antiretroviral drugs. It works by inhibiting HIV viral protease and inhibiting viral replication (reproduction), thereby preventing infection. Ritonavir belongs to a class of drugs called protease inhibitors. It prevents HIV from multiplying in the body.

[Indications]

This product is suitable for use in combination with other antiretroviral drugs to treat human immunodeficiency virus (HIV-1) infection in adults and children over 2 years old.

Experience with lopinavir and ritonavir mainly comes from patients who have not received antiretroviral drugs. Data on patients who have received protease inhibitors are very limited. There are also very limited data on rescue therapy in patients who fail lopinavir-ritonavir. Whether HIV-1 infected patients who have received protease inhibitor treatment chooses this product for treatment mainly depends on two factors, namely the patient's individual viral resistance test results and his treatment history.

[Usage and Dosage]

This product should be swallowed whole and should not be chewed, broken or crushed.

Adults and Adolescents: The recommended dose of this product is 400/100mg (2 tablets), twice daily. Can be taken with or without food.

Children (2 years old and above): The recommended dose of this product is 400/100mg (2 tablets), twice a day. It can be used for children weighing 40kg or more or children with a body surface area greater than 1.4㎡. For weight less than 40 kg or BSA between 0.6 and 1.4 m2 and children who can swallow tablets, please refer to the dosage of this product 100/25mg.

[Adverse reactions]

The most common adverse reactions are diarrhea, nausea, vomiting, hypertriglyceridemia and hypercholesterolemia. Diarrhea, nausea, and vomiting may occur at the beginning of treatment, and hypertriglyceridemia and hypercholesterolemia may appear later.

[Notes]

1. Hepatic insufficiency: In patients with mild to moderate hepatic insufficiency, the exposure dose of lopinavir increases by approximately 30%, but this increase has no clear correlation with clinical treatment. There are no data on patients with severe hepatic impairment and this product should not be used in these patients.

2. Renal insufficiency Because the renal clearance rate of lopinavir and ritonavir is very small, patients with renal insufficiency will not experience an increase in blood drug concentration. Because both lopinavir and ritonavir are strongly protein-binding, hemodialysis or peritoneal dialysis does not significantly affect their clearance.